Ceapro

Ceapro — Investor Presentation (February 2015)

32 slides from Ceapro's investor presentation, February 2015

  1. Slide 1: Corporate Presentation

    TSX-V: CZO Corporate Presentation 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements, including those predicting the timing of product development and launches. Although the company believ

  3. Slide 3: Overview

    Overview • Canadian leader in botanical actives innovation and bioprocessing o Proprietary plant extraction based manufacturing process o Active ingredients for health care and cosmetic industries • Two active ingredients currently used in household name products - Cosmetics & Personal Care o Beta G

  4. Slide 4: Ceapro's Core Expertise

    Ceapro’s Core Expertise The identification, extraction and purification of active compounds from natural sources… …which allows us to create innovative ingredients for the personal and healthcare industries …We are a Green Company! 4

  5. Slide 5: Proprietary plant extraction based manufacturing

    Proprietary plant extraction based manufacturing Beta Glucan Avenanthramides Lupinus angustifolia And Avena sativa 5

  6. Slide 6: Unique Bioprocessing Expertise

    Unique Bioprocessing Expertise • Ability to isolate and purify specific molecules from a wide range of botanical sources • Prototype extracts are then prepared for bio-screening or in vivo testing • Unique drying (heat-free) technology for sensitive compounds • Commercialized unique bio-actives from

  7. Slide 7: New & Innovative Technologies: PGX Spray Drying

    New & Innovative Technologies: “Pressurized Gas Expanded (PGX) Liquid –Spray Drying” 7

  8. Slide 8: CNC before and after PGX drying

    CNC before and after PGX drying • Production of biomaterials from different industries 0.5 g CNC 0.5 g CNC Spray Dried PGX Dried CNC AEROGEL Density : 0.006 g/cm3

  9. Slide 9: Application of PGX-CNC

    Application of PGX-CNC • Applications of PGX-CNC • Wound healing, scaffolds • Drug delivery • Absorbants • Composite-Plastics • Paints • PGX processing allows processing of high value biopolymers: • Beta Glucan • Chitosan • Gum Arabic • CNC

  10. Slide 10: Market Sectors (Current & Future)

    Market Sectors (Current & Future) Cosmetics & Personal Care • Anti-Inflammation • Anti-Ageing Nutraceuticals/Functional Foods • Metabolic Diseases Pharma/OTC(Botanic Drugs) • Wound Healing • Metabolic Diseases 10

  11. Slide 11: Cosmetics - From Field to Formulation

    Cosmetics - From Field to Formulation Field Research Manufacturing Consumer Identify Discover Develop Provide Novel Unique Functional Innovative Innovative Plants Actives Processes Products 11

  12. Slide 12: Beta Glucan and Avenanthramides in Multiple Household Products

    Beta Glucan and Avenanthramides in Multiple Household Products • Aveeno • Coppertone • Jergens • Dove • Lubriderm • Burt’s Bees • 3M –Nexcare • The Body Shop • KY Products • Philosophy • Neutrogena • ROC 12

  13. Slide 13: A Hidden Gem....

    A Hidden Gem…. 13

  14. Slide 14: Ceapro – Our Value Drivers

    Ceapro – Our Value Drivers Beta glucan Avenanthramides 14

  15. Slide 15: Beta Glucan

    Beta Glucan • Beta glucan is a soluble fibre found in the call walls of oat kernels • Acts as a natural moisture barrier and film-forming agent • Relieves and alleviates dry and itchy skin by replenishing and protecting the skin’s moisture barrier • Provides hydration against the drying effects of t

  16. Slide 16: Beta Glucan in Cosmeceuticals

    Beta Glucan in Cosmeceuticals • Ceapro was the first to demonstrate that high molecular weight beta glucan can penetrate human skin. • Dermatology applications range from anti-ageing to wound healing. • New highly purified beta glucan powder successfully developed to address new market demands/trend

  17. Slide 17: Natural Skin Restructuring Agent

    Natural Skin Restructuring Agent • Proven to effectively reduces fine lines & wrinkles • Forms a natural barrier protecting skin • Wound healing agent – films or gels • Sustained release of active agents requiring enhanced percutaneous transportation 17

  18. Slide 18: Avenanthramides

    Avenanthramides • Antihistamine and anti- inflammatory properties • Potential benefits in the control of inflammation- based diseases 18

  19. Slide 19: Avenanthramides Clinically Proven in Cosmeceuticals

    Avenanthramides Clinically Proven in Cosmeceuticals Significant improvements in erythema symptoms associated in subjects with mild to moderate atopic dermatitis • 40% improvement in itch perception after 1 week • 62% of patients showed an improvement in their skin condition Subjects with atopy • 89%

  20. Slide 20: Our Value Drivers – Advanced Skin Care

    Our Value Drivers – Advanced Skin Care Skin inflammation is a complex physiological process Beta glucan Beta glucan • Accelerates tissue healing • Deep hydrating agent • Improves elasticity • Natural film protective barrier Avenanthramides • Relief from itching (Pruritus) • Reduces inflammation and

  21. Slide 21: Robust Growth Strategy

    Robust Growth Strategy • Generate scientific data to support current product indications • Pursue new indications for current product portfolio from research programs • Develop new products in accordance with needs expressed by customers Cosmeceuticals • Improve manufacturing technologies • Look for

  22. Slide 22: Beta Glucan in Nutraceuticals and Pharmaceuticals

    Beta Glucan in Nutraceuticals and Pharmaceuticals • Potential reduction of cardiovascular and heart diseases risk o Acts to decrease LDL and total cholesterol • Proprietary beta glucan drug-delivery platform o Shown to effectively penetrate into the skin, into the deep layers as well as into the ski

  23. Slide 23: Avenanthramides in Nutraceuticals and Pharmaceuticals

    Avenanthramides in Nutraceuticals and Pharmaceuticals • Avenanthramides shown to attenuate exercise-induced inflammation in animal studies • Human clinical studies showed that dietary avenanthramides supplements significantly reduced inflammation biomarkers in an elderly population • New process tec

  24. Slide 24: Value Drivers

    Value Drivers Cosmeceuticals - Current and new indications-Base Business Nutraceuticals - New product development-Near Term Catalyst Pharmaceuticals - New products, new partnership discussions Manufacturing Innovation - New processes, higher output, lower cost 24

  25. Slide 25: New Bio-processing Facility

    New Bio-processing Facility • R&D • Pilot Scale Capability • Commercial Production New 21,000 sq. ft. GMP Bio-processing Extraction Facility in Edmonton, Alberta 25

  26. Slide 26: Value-Driving Milestones

    Value-Driving Milestones 2015 - H1 2015 - H2 2016 - H1 2016 - H2 New Manufacturing Facility Commercial scale-up of dry powder technology platform Ceapro in Nutraceuticals and Pharmaceuticals Beta Glucan preclinical studies Beta Glucan Pilot Phase Avenanthramides Phase ½ 26

  27. Slide 27: Financial Profile - TSX-V: CZO

    Financial Profile - TSX-V: CZO TSX-V: CZO Stock Ticker $43,000,000 Market capitalization as of January 2, 2015 61,420,000 Common shares outstanding Total sales for the nine-month period ending $6,831,000 September 2014 $4,000,000 Total amount of grant-based-funding raised to date 27

  28. Slide 28: Financial Performance 2009-2013

    Financial Performance 2009-2013 8000 6000 4000 2000 0 2009 2010 2011 2012 2013 -2000 Revenue Income (loss) from Operations ($000) 28

  29. Slide 29: Financial Performance First 9 months 2014 vs 2013

    Financial Performance First 9 months 2014 vs 2013 (in 000’s) $8 000 $7 000 $6 000 $5 000 $4 000 $3 000 $2 000 $1 000 $0 2013 2014 Revenue Net Income 29

  30. Slide 30: Recent Positive Momentum

    Recent Positive Momentum 12/18 - Ceapro Enters 12/4 - Research Grant into Financing from Alberta Innovates $0,80 Agreement Bio Solutions $0,70 11/20 - Appoints William W. Li, M.D. to $0,60 Board of Directors 11/14 - Third Quarter $0,50 2014 Financial Results Price 7/30 - Second Quarter $0,40 2014 Fi

  31. Slide 31: Ceapro is Poised for an Exciting 2015

    Ceapro is Poised for an Exciting 2015 A Solid Company!  Profitable  Highly-experienced, results-driven team  Operational efficiency  Solid innovative science/IP  Commercially accepted products  Expanded Marketing/Sales territories  Strong development Pipeline for long-term sustainable growth

  32. Slide 32: Thank you!

    Thank you! www.ceapro.com 32

Ceapro — Investor Presentation (February 2015) on 6ix